secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269468
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OnKure Q3 net loss $14.7M; cash $70.3M; initial data from PI3K trial pushed to Q1 2026
--------------------------------------------------------------------------------

- Cash $70.3M as of Sept 30, 2025; expected to fund operations into Q4 2026.
- Net loss $14.7M ($1.09/share) vs $11.6M loss in Q3 2024.
- First patients dosed in two triplet arms of PIKture-01: fulvestrant+ribociclib and trastuzumab+tucatinib.
- Initial clinical data from monotherapy and fulvestrant arms now expected Q1 2026.
- Next-gen PI3Kα pan-mutant inhibitor candidate selection announced; more details Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312525269468/0001193125-25-269468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312525269468/okur-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer